ライフサイエンスコーパス: tumor initiating cell

1 dictated by the proliferative status of the tumor-initiating cell.

2 es are separable based on the lineage of the tumor-initiating cell.

3 t in primary CRC, which potentially includes tumor initiating cells.

4 he elimination of undifferentiated stem-like tumor initiating cells.

5 from noisy expression data of CD44+CD24-/low tumor initiating cells.

6 gene target expression segregate to CD133(+) tumor initiating cells.

7 operties of 3T3 fibroblasts and glioblastoma tumor initiating cells.

8 nomic profile of residual, therapy resistant tumor initiating cells.

9 odulating the lineage potential of MMTV-Wnt1 tumor initiating cells.

10 nt of effective therapeutic agents targeting tumor-initiating cells.

11 ttributed to the presence of CD44-expressing tumor-initiating cells.

12 t attenuation of tumorigenicity by targeting tumor-initiating cells.

13 ewal is thought to be a critical property of tumor-initiating cells.

14 and also has been linked to the capacity of tumor-initiating cells.

15 and lung metastases are highly enriched for tumor-initiating cells.

16 dentify MELK as a potential target in breast tumor-initiating cells.

17 r eradication of primary tumors derived from tumor-initiating cells.

18 hology, suggesting a mixed-lineage origin of tumor-initiating cells.

19 say, a Lin(-)CD29(H)CD24(H) subpopulation of tumor-initiating cells.

20 gating the normal differentiation program of tumor-initiating cells.

21 sis, providing signals that maintain mammary tumor-initiating cells.

22 ed to be resistant to chemotherapy caused by tumor-initiating cells.

23 t Rspo1 and the Sca1-population, enriched in tumor-initiating cells.

24 emalignant cells and activates quiescence in tumor-initiating cells.

25 oRNA-203 promotes selection and expansion of tumor-initiating cells.

26 ions suggest an active selection process for tumor-initiating cells.

27 nses to NOTCH3 and expands therapy-resistant tumor-initiating cells.

28 ected strategy of immunotherapy to eradicate tumor-initiating cells.

29 ignature similar to that observed for human 'tumor-initiating' cells.

30 flammatory cytokine production, and increase tumor-initiating cell abundance and metastatic progressi

31 the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently av

32 in turn, regulate the relative proportion of tumor initiating cells and the latency of her-2-driven t

33 the mTORC1 kinase induces differentiation of tumor-initiating cells and allows their subsequent deple

34 at the oncofetal protein 5T4 is expressed on tumor-initiating cells and associated with worse clinica

35 mal transition-driving genes, reminiscent of tumor-initiating cells and claudin-low breast cancer.

36 ed endothelial cells (TDECs) originated from tumor-initiating cells and did not result from cell fusi

37 horylated by a Jak2-mediated pathway only in tumor-initiating cells and in human SHH-type medulloblas

38 to maintain proper exon recognition in brain tumor-initiating cells and may provide new inroads for n

39 at the intersections of stem cell function, tumor-initiating cells and multilineage tumor developmen

40 ms by which RA targets GBM-derived stem-like tumor-initiating cells and novel targets applicable to d

41 However, tumor-initiating cells and the biological processes that

42 ined a mixture of red cells (PDGF-expressing/tumor-initiating cells) and green cells (recruited proge

43 iforme (GBM) research is the identity of the tumor-initiating cell, and its contribution to the malig

44 mor cell growth, decreased the proportion of tumor-initiating cells, and decreased tumor formation in

45 resistance, identification of stem cells and tumor-initiating cells, and development of mouse models

46 This osteosarcoma tumor-initiating cell appears highly prolific and consti

47 and cell deformability, and demonstrate that tumor-initiating cells are less differentiated in terms

48 Cancer stem cells (CSCs), or tumor-initiating cells, are involved in tumor progressio

49 ng possibility that these cells could be the tumor-initiating cells, as has been suggested for adult

50 rowth through the generation or expansion of tumor initiating cells bearing stem-like characteristics

51 onchio-alveolar stem cells (BASCs), putative tumor-initiating cells, both in vitro and in vivo.

52 Breast tumors may derive from self-renewing tumor-initiating cells (BT-ICs), which contribute to tum

53 nd has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.

54 enic signaling by NOTCH is elevated in brain tumor-initiating cells (BTIC) in malignant glioma, but t

55 bolic dysregulation in patient-derived brain tumor-initiating cells (BTIC) to a nexus between MYC and

56 Brain tumor initiating cells (BTICs) co-opt the neuronal high

57 to tumor progression by enriching for brain tumor initiating cells (BTICs) owing to preferential BTI

58 Brain tumor initiating cells (BTICs), also known as cancer ste

59 eractions modulate the galvanotaxis of brain tumor initiating cells (BTICs).

60 Here we used brain tumor-initiating cells (BTICs) and show that BTICs expre

61 e et al. determined that GSI-resistant brain tumor-initiating cells (BTICs) from GBM express a higher

62 Brain tumor-initiating cells (BTICs) have been identified as k

63 m cell regulatory pathways to maintain brain tumor-initiating cells (BTICs), also known as cancer ste

64 rtance of TrkB and TrkC in survival of brain tumor-initiating cells (BTICs).

65 duced tumors contained a large percentage of tumor-initiating cells, but these were reduced significa

66 e tumor growth, angiogenesis, metastasis and tumor-initiating cells by in vivo imaging and provide a

67 An accumulation of tumor-initiating cells can be found in 2% to 50% of all

68 The concept that tumor-initiating cells can co-opt the self-renewal progr

69 CD133+ tumor-initiating cells can originate from proliferating

70 Cancer stem cells are proposed to be tumor-initiating cells capable of tumorigenesis, recurre

71 Tumor-initiating cells (CD44(+)) have been described for

72 Fbeta drives Notch1-mediated EMT to generate tumor initiating cells characterized by high CD44 expres

73 proposed to be composed of two compartments: tumor-initiating cells characterized by a slow and asymm

74 )CXCR4(+) (CXC receptor 4) colorectal cancer tumor-initiating cells (Co-TICs) and the LN stromal micr

75 Cancer stem cells (CSC; also called tumor-initiating cells) comprise tumor cell subpopulatio

76 Cancer stem cells (CSCs), or tumor-initiating cells, comprise a subset of tumor cells

77 e showed recently that cancer stem cells, or tumor-initiating cells, derived from human glioblastoma

78 p19(ARF) profoundly influences the nature of tumor-initiating cells during BCR/ABL-mediated leukemoge

79 ell tracking method to follow up the fate of tumor-initiating cells during chemotherapy.

80 ations, as well as the CD61(high)CD49f(high) tumor-initiating cell-enriched population.

81 These tumor-initiating cells express stem cell markers.

82 tiation in prostate progenitors, presumptive tumor initiating cells for prostate cancer.

83 of cancer.(1-4) The nature and existence of tumor-initiating cells for leukemia and other malignanci

84 xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.

85 he growth of a range of tumor types, reduces tumor-initiating cell frequency, and exhibits synergisti

86 ink colitis and cancer identifying potential tumor-initiating cells from colitic patients, suggesting

87 d basal-like TNBC tumors in mice and blocked tumor-initiating cell function and macrometastasis.

88 n expression of antigens thought to identify tumor initiating cells, generation of 3D aggregates when

89 novel HSP90 inhibitor, NVP-HSP990, in glioma tumor-initiating cell (GIC) populations, which are stron

90 t brain tumor, harbors a small population of tumor initiating cells (glioblastoma stem cells) that ha

91 rmation and viability of primary human colon tumor-initiating cells harboring mutant KRAS.

92 ther tumor cell holoclones genuinely contain tumor-initiating cells has not been directly addressed.

93 Tumor-initiating cells have been suggested to be rare in

94 , the mechanisms that regulate quiescence in tumor-initiating cells have not been analyzed in detail

95 ulations called cancer stem cells (CSCs), or tumor-initiating cells, have been defined in functional

96 astic modulus induced in 3T3 fibroblasts and tumor initiating cells in response to agents that soften

97 ed in airway epithelial repair that may be a tumor-initiating cell in lung cancer and which may be as

98 We explored the nature of the tumor-initiating cell in osteosarcoma, a bone malignancy

99 terogeneity between tumor-initiating and non-tumor-initiating cells in glioblastoma.

100 tify the entire population of epithelial and tumor-initiating cells in human metastatic colon cancer.

101 em cells or intermediate progenitors are the tumor-initiating cells in lola mutants.

102 However, the precise contribution of CD133+ tumor-initiating cells in mediating colon cancer metasta

103 in signaling can further demarcate high-ALDH tumor-initiating cells in the nondysplastic epithelium o

104 that reparative K14+ progenitor cells may be tumor-initiating cells in this subgroup of smokers with

105 erapeutic agents is effective in killing the tumor-initiating cells in vitro and inhibits tumor forma

106 nation in inducing differentiation of breast tumor-initiating cells in vivo Furthermore, gene express

107 astasis, and recurrence, and targeting these tumor-initiating cells is necessary to eradicate tumors.

108 that human malignant glioma tissues and also tumor-initiating cells isolated from fresh human maligna

109 eficiencies) that were derived from CD44(hi) tumor-initiating cells isolated from PCa-20a cells.

110 The tumor-initiating cells isolated from these tumors that f

111 CNOT3 expression, as might be expected for a tumor-initiating cell marker.

112 val in brain tumors and other cancers; thus, tumor initiating cells may extract nutrients with high a

113 in pre-malignant DCIS lesions and that these tumor-initiating cells may determine the phenotype of DC

114 e viability and maintenance of self-renewing tumor-initiating cells may ultimately lead to improved t

115 nd by increased reliance of cancer cells and tumor-initiating cells on mitochondria, resulting in pot

116 od that enriches cancer stem cells (CSCs) or tumor-initiating cells on the basis of cell adhesion pro

117 for tumor initiation and propagation, termed tumor initiating cells or cancer stem cells (CSCs).

118 y a reservoir of self-renewing cells, termed tumor-initiating cells or cancer stem cells.

119 n epithelial-to-mesenchymal transition and a tumor initiating cell phenotype, and that it is required

120 PKCiota-ELF3-NOTCH3 signaling controls the tumor-initiating cell phenotype by regulating asymmetric

121 the Lin(-)CD29(H)CD24(H) mouse mammary gland tumor-initiating cell population include those involved

122 Focusing on one example of a tumor-initiating cell population, we demonstrate that th

123 pigenomic profiling revealed that IFE and HF tumor-initiating cells possess distinct chromatin landsc

124 ), consistent with the selective survival of tumor-initiating cells posttreatment.

125 elf-renewal, acting in a small population of tumor-initiating cells present in tumors.

126 r subpopulation, termed cancer stem cells or tumor-initiating cells, promotes therapeutic resistance

127 The identification of tumor-initiating cells represents a significant challeng

128 uding glioma stem cells (GSC), which are the tumor-initiating cells responsible for treatment failure

129 tumors, which are driven by a component of 'tumor-initiating cells' retaining stem cell properties.

130 ddition to angiogenic effects, VEGF promotes tumor-initiating cell self-renewal through VEGFR-2/STAT3

131 140/SOX2 pathway critically regulates breast tumor-initiating cell survival, providing a new link bet

132 ribe the isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary hu

133 t evidence has demonstrated the existence of tumor-initiating cells (T-ICs) as the culprit for treatm

134 r can arise from a cancer stem cell (CSC), a tumor-initiating cell that has properties similar to tho

135 Human melanomas contain a population of tumor-initiating cells that are able to maintain the gro

136 existence of a small population of CD133(+) tumor-initiating cells that are capable of regenerating

137 own about chromatin mechanisms that regulate tumor-initiating cells that are proposed to be responsib

138 fectively eliminate the subpopulation of GBM tumor-initiating cells that are responsible for relapse.

139 The effectiveness of CD133NPs in reducing tumor initiating cell (TIC) fraction was investigated us

140 in pancreatic cancer along with a decreased tumor initiating cell (TIC) population in pancreatic tum

141 al-mesenchymal transition (EMT), promoting a tumor-initiating cell (TIC) phenotype characterized by i

142 Tumor-initiating cells (TIC) are critical yet evasive ta

143 Tumor-initiating cells (TIC) are dynamic cancer cell sub

144 ALDH1(+)CD44(+) cells are putative tumor-initiating cells (TIC) in head and neck squamous c

145 f) receptor 2 (CCR2) decreases the number of tumor-initiating cells (TIC) in pancreatic tumors.

146 Understanding the mechanisms supporting tumor-initiating cells (TIC) is vital to combat advanced

147 Breast tumor-initiating cells (TIC) may contribute to tumor pro

148 Emerging evidence indicates the presence of tumor-initiating cells (TIC) or cancer stem cells in ost

149 Tumor-initiating cells (TIC) perpetuate tumor growth, en

150 ypothesis that HER2/HER3 signaling in breast tumor-initiating cells (TIC) promotes self-renewal and s

151 Tumor-initiating cells (TIC) represent cancer stem-like

152 play cellular hierarchies with self-renewing tumor-initiating cells (TIC), also known as cancer stem

153 y organized and driven by a subpopulation of tumor-initiating cells (TIC), or cancer stem cells.

154 In examining the role of EGFR in tumor-initiating cells (TIC), we found that EGFR express

155 inflammatory markers and spheroid-generating tumor-initiating cells (TIC).

156 ibitors, in particular those that can target tumor-initiating cells (TIC).

157 microenvironment to promote proliferation of tumor initiating cells (TICs) and carcinogenesis.

158 Isolating tumor initiating cells (TICs) often requires screening o

159 rogression and relapse is conceivably due to tumor initiating cells (TICs)/cancer stem cells.

160 ene expression signatures derived from human tumor-initiating cells (TICs) and human mammary stem cel

161 s by activating JAK/STAT signaling in breast tumor-initiating cells (TICs) and promoted TIC self rene

162 east cancer cells bearing characteristics of tumor-initiating cells (TICs) and that strongly associat

163 Tumor-initiating cells (TICs) are a sub-population of ce

164 To determine if tumor-initiating cells (TICs) are present in SCCas, we u

165 Tumor-initiating cells (TICs) are thought to be critical

166 These distinct tumor-initiating cells (TICs) clonally recapitulated the

167 rogression in cancer requires populations of tumor-initiating cells (TICs) endowed with unlimited sel

168 Tumor-initiating cells (TICs) have been shown both exper

169 (MECs) to mammary stem cells (MaSCs) and to tumor-initiating cells (TICs) have not been entirely elu

170 The proportion of tumor-initiating cells (TICs) in the mammary tumors from

171 dentification of therapeutic targets against tumor-initiating cells (TICs) is a priority in the devel

172 ucing kinase (NIK), support the expansion of tumor-initiating cells (TICs) that copurify with a CD24(

173 Moreover, GDF15 induces the expansion of MM tumor-initiating cells (TICs), and changes in the serum

174 of cancer in which only a fraction of cells, tumor-initiating cells (TICs), can sustain tumor growth.

175 lentiviral particles, and transduction into tumor-initiating cells (TICs), followed by in vivo trans

176 o has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and che

177 oncogene-induced expansion and activities of tumor-initiating cells (TICs), whereas it is largely dis

178 njury and establishes selective pressure for tumor-initiating cells (TICs), which proliferate to form

179 ssed in and regulates self renewal of breast tumor-initiating cells (TICs).

180 n by a population of stem-like cells, called tumor-initiating cells (TICs).

181 bserved in a genetic model of ovarian cancer tumor-initiating cells (TICs).

182 ancy-associated traits and the properties of tumor-initiating cells (TICs).

183 as been attributed to expansion of stem-like tumor-initiating cells (TICs).

184 drugs that specifically target glioblastoma tumor-initiating cells (TICs).

185 ncer of Zeste Homolog 2 (EZH2) and increased tumor-initiating cells (TICs).

186 ane transport in bulk tumor cells (BTCs) and tumor-initiating cells (TICs).

187 gulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells.

188 ds on a small subset of tumor cells, called "tumor-initiating cells" (TICs), with SC-like properties.

189 C receptors by ligands BDNF and NT3 enhances tumor-initiating cell viability through activation of ER

190 that breast cancer is derived from a single tumor-initiating cell with stem-like properties, but the

191 Within established GBM, a subpopulation of tumor-initiating cells with stem-like properties (GBM st

192 ver, interaction of accessory cells with the tumor-initiating cell within the microenvironment is oft